StockData
ResMed Inc logo

ResMed Inc (RSMDF) stock

RSMDFOTCSurgical & Medical Instruments & ApparatusFiscal year ends June 30Also trades as RMD
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 13, 2026Score 21/3011% below fair value
$22.61+0.00 (0.00%)

Close on Oct 19, 2026Market cap $33.17BP/E 22.0Yield 1.04%

ResMed Inc grew revenue 9.9% to $5.65B over the twelve months to Jun 30, 2026. Operating income rose 11.9% to $1.89B, moving the operating margin from 32.7% to 33.4%. Free cash flow was $1.65B, down 0.7% from a year earlier. At the latest close the market valued the company at $33.17B, 22.0 times its earnings.

Revenue
$5.65B
+9.9% vs. a year earlier
Operating income
$1.89B
+11.9% vs. a year earlier
Free cash flow
$1.65B
-0.7% vs. a year earlier
EPS, diluted
$10.43
+9.7% vs. a year earlier

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$33.17B
P/E ratio
22.0
Price to sales
5.87
Price to book
5.04
Dividend yield
1.04%
Free cash flow yield
4.97%

Fundamentals

Revenue
$5.65B
Net income
$1.52B
EPS, diluted
$10.43
Free cash flow
$1.65B
Book value per share
$45.38
Diluted shares
145M

Trading

Next earnings
Jan 28, 2027 (estimated, after the close)
Previous close
$22.61
Open
$22.61
Day's range
$22.61 – $22.61
Volume
0
Beta (5 years)
0.91
52-week range
$180.26 – $277.67
RSI (14 days)
41.8
Volatility (1 year)
30.1%
Relative volume
2.56×
WACC
9.5%

Market cap history

Month-end market cap since 2009, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodRSMDFS&P 500DifferenceRSMDF per yearS&P 500 per year
1 month0.0%+0.6%−0.6 pts
3 months+35.6%+3.4%+32.2 pts
Year to date-14.6%+13.3%−27.8 pts
1 year-7.5%+16.6%−24.2 pts
3 years+58.1%+86.4%−28.3 pts+16.5%+23.1%
5 years-5.1%+81.9%−86.9 pts-1.0%+12.7%
10 years+269.6%+318.9%−49.2 pts+14.0%+15.4%

Fifteen years at a glance

Fiscal years 2012 to 2026, USD

Revenue

$5.65B+9.9% YoY

Gross profit

$3.45B+13.0% YoY

Operating income

$1.89B+11.9% YoY

Net income

$1.52B+8.8% YoY

EPS, diluted

$10.43+9.7% YoY

Free cash flow

$1.65B-0.7% YoY
Reported period

Press releases

Releases ResMed filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About ResMed

Surgical & Medical Instruments & Apparatus

ResMed Inc. develops digital health solutions, cloud-connected medical devices, and care management software platforms. The company operates through two business segments: Sleep and Breathing Health, and Residential Care Software. Its core offering includes continuous positive airway pressure systems, bilevel and adaptive servo-ventilation equipment, ventilators, diagnostic products, mask systems, and cloud applications like AirView and myAir. In addition, it provides residential care management platforms, including Brightree and MEDIFOX DAN. Its solutions serve individuals with sleep apnea and respiratory conditions, alongside clinicians, durable medical equipment suppliers, and residential healthcare organizations.

Company profile, executives and history

ResMed stock: common questions

What is ResMed's stock price?

RSMDF closed at $22.61 on Oct 19, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $180.26 and $277.67.

What is ResMed's market cap?

ResMed was worth $33.17B at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is RSMDF's P/E ratio?

RSMDF trades at 22.0 times earnings, based on diluted earnings per share of $10.43 over the twelve months to Jun 30, 2026.

How much revenue does ResMed make?

ResMed reported revenue of $5.65B for the twelve months to Jun 30, 2026, up 9.9% from a year earlier.

Does ResMed pay a dividend?

Yes. ResMed paid $2.40 per share over the last twelve months, a yield of 1.04% at the latest price, and has raised its annual dividend 5 years in a row.

When does ResMed report earnings next?

ResMed is expected to report Q2 FY2027 results on Jan 28, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has RSMDF stock performed over the past year?

Including dividends, RSMDF returned -7.5% over the past year, against +16.6% for the S&P 500.

Who are ResMed's competitors?

Companies most similar to ResMed by business, industry and size include SOLV, BAX, DXCM, MMED, ICUI.